What About Variant Histologies in Bladder Cancer?
Authors:
- 6 June 2024
- journal article
- review article
- Published by Elsevier in European Urology Focus
- Vol. 10 (2) , 227-230
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)Annals of Oncology, 2023
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 GuidelinesEuropean Urology, 2023
- Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 TrialClinical Cancer Research, 2022
- The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract TumorsEuropean Urology, 2022
- Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic VariantsFrontiers in Oncology, 2022
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment ModalitiesClinical Genitourinary Cancer, 2021
- What Is the Significance of Variant Histology in Urothelial Carcinoma?European Urology Focus, 2020